Your retina has two types of light-sensing cells: rods (for night vision and side vision) and cones (for daytime and color vision). In retinitis pigmentosa, a genetic mutation tells the rod cells to self-destruct, starting at the outer edges of your retina [5]. Night blindness is the first symptom because rods are most active in dim light—so you notice it when driving at dusk or walking into a dark room.
The rod-cell death spreads inward over time, like a shrinking circle of vision. Your peripheral (side) vision narrows first, then central vision may fade in later stages [1]. This happens because the genetic defect is present from birth, but rod cells die slowly—sometimes over 20–40 years—so you don't notice until your 20s or 30s.
About 95% of retinitis pigmentosa cases are inherited (autosomal recessive, autosomal dominant, or X-linked), meaning the mutation runs in families [5]. The remaining 5% are sporadic (new mutations). Genetic testing identifies your specific mutation—RPGR, PDE6A, PDE6B, PRPH2, or others—which determines your treatment options and how fast your vision will likely decline.
Retinitis pigmentosa is not painful and does not cause complete blindness in most people, but it does shrink your usable vision over time. Early detection and genetic testing unlock access to gene therapy, clinical trials, and medications that can slow rod-cell death [2].